Methoxy Polyethylene Glycol-Epoetin Beta

CHEMBL3707314 Phase 4 Zugelassen Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A long-acting erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease. It stimulates the bone marrow to produce more red blood cells, reducing the need for blood transfusions.

Therapeutische Bereiche

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A long-acting erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease. It stimulates the bone marrow to produce more red blood cells, reducing the need for blood transfusions.

Yes, Methoxy Polyethylene Glycol-Epoetin Beta is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707314. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.